Beyond Air, Inc. XAIR 深 滬
等待開盤 02-07 09:30:00 美东时间
1.15
+0.105
+10.05%
華盛通- 最 高1.15
- 今 開1.08
- 成交量 33.35万股
- 最 低 1.055
- 昨 收 1.045
- 總市值 1210.87万
- 52周最高 7.968
- 市盈率 靜 --
- 換手率 3.17%
- 52周最低 0.6733
- 委 比 -33.65%
- 總股本 1052.93万
- 歷史最高 328.20
- 量 比 1.13
- 振 幅 9.09%
- 歷史最低 0.7311
- 每 手 1
- 風險率 1.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多XTL Update on Recent Developments
XTL Biopharmaceuticals Ltd. is working to finalize the acquisition of 85% of NeuroNOS Ltd. from Beyond Air Inc., following a binding letter of intent signed on January 13, 2026. The company plans to hold a shareholders' meeting on February 17, 2026, to approve a private placement of up to $2 million. The transaction and private placement aim to address the company's deficiency under Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5...
01-29 21:05
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast
Beyond Air Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company, will report its third fiscal quarter 2025 financial results on February 13, 2026. A conference call and webcast will be held at 8:00 am ET that day. The call can be accessed domestically via 1-877-407-0784 or internationally via 1-201-689-8560 using conference ID 13758405. A webcast will also be available on the company’s website, with a replay one hour post-call. Bey...
01-26 21:05
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) received a notification from Nasdaq stating it doesn't meet the minimum $2.5 million stockholders' equity requirement for continued listing. The company reported a stockholders' equity deficit of $47,000 as of June 30, 2025, and doesn't meet alternatives for market value or net income. Nasdaq did not delist the company's ADSs immediately but gave XTL until March 6, 2026, to submit a compliance plan, with...
01-23 21:10
美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
D. Boral Capital Maintains Buy on Beyond Air, Maintains $11 Price Target
D. Boral Capital analyst Jason Kolbert maintains Beyond Air (NASDAQ:XAIR) with a Buy and maintains $11 price target.
01-21 20:20
Why Is Beyond Air Stock (XAIR) Up Today?
Beyond Air stock gained after subsidiary NeuroNOS reached an agreement with XTL...
01-13 21:23
Beyond Air shares are trading higher after XTL Biopharmaceuticals agreed to acquire an 85% stake in its NeuroNOS subsidiary with Beyond Air set to receive up to $32.5 million in upfront, development and commercial milestone payments.
Beyond Air shares are trading higher after XTL Biopharmaceuticals agreed to acq...
01-13 20:34
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
XTL Biopharmaceuticals has entered a binding agreement to acquire 85% of NeuroNOS Ltd., a biotech company developing disease-modifying therapies for autism. The deal underscores the urgent need for effective autism treatments, with 1 in 31 U.S. children affected and no FDA-approved therapies targeting the core pathology. NeuroNOS, led by renowned autism researcher Prof. Haitham Amal and two Nobel Laureates in Chemistry, focuses on addressing nitr...
01-13 12:30
Beyond Air appoints Dan Moorhead as CFO
Beyond Air (XAIR) announced on Tuesday the appointment of Dan Moorhead as chief financial officer (CFO), effective January 5, 2026. From June 2017 to August 2025, Moorhead served as chief financial o...
2025-12-30 20:38
Beyond Air® Appoints Dan Moorhead as Chief Financial Officer
Beyond Air, Inc. appoints Dan Moorhead as Chief Financial Officer, effective January 5, 2026. Moorhead brings over 20 years of finance leadership experience, including roles at Zynex, Inc. and Evolving Systems, Inc. The Company granted him an inducement stock option award under Nasdaq rules. Beyond Air specializes in nitric oxide therapies and is advancing LungFit PH and other LungFit systems for respiratory treatments, with FDA approval pending ...
2025-12-30 12:30
